Vonolazan is undoubtedly a gold withdrawing antigastric drug, however, there is also some dissatisfaction with this drug due to previous corporate R & D failures with the p-cab class of drugs and intense competition for PPIs on the market. Even then, domestic firms still took the first time to declare vonolazan.